About My Health Careers Internship MedBlogs Contact us

Molecular Signature to Predict Response to Cancer Therapy

by Rajashri on September 8, 2009 at 8:33 PM
Font : A-A+

 Molecular Signature to Predict Response to Cancer Therapy

A molecular signature that that helps account for the aggressive behavior of a variety of cancers may also help identify patients who are likely to respond to a particular anti-cancer drug, according to American scientists.

Researchers at the Moores Cancer Center at the University of California-San Diego (UCSD) say that their findings may lead to a personalized approach to treatment for a variety of solid tumours that are currently resistant to therapies.


In a study, they have found that a receptor sitting on the surface of certain aggressive tumour cells can activate a key enzyme, src-kinase, which helps tumour cells to become more aggressive in the body.

Writing in their study report, the researchers have pointed out that this enzyme is the target of the anticancer drug dasatinib, which blocks its activity and is currently approved for treating chronic myelogenous leukemia (CML).

They further state that the scientists the presence of the receptor - a protein called integrin alpha-v beta-3 - on some of the more common solid tumors such as breast, colon, lung and pancreas could help identify individuals with many other types of cancer that are also likely to respond to the drug.

"These results could enable us to identify the subpopulation of cancer patients who are likely to respond to treatment with dasatinib," Nature magazine quoted Dr. David Cheresh, professor and vice chair of pathology at the UC San Diego School of Medicine and the Moores UCSD Cancer Center, who led the work, as saying.

"Rather than treat all patients with a given tumor type the same way, by identifying a specific molecular signature consisting of the receptor and its activated enzyme, we can customize the treatment in such a way that we impact the patients most likely to be sensitive to a drug," he added.

During the study, the researchers compared the growth properties of pancreatic and breast cancer cells that expressed the alpha-v beta-3 receptor with those that did not.

Their effort led to the discovery of a molecular pathway that accounted for the increased malignancy.

"Once we identified the pathway, we immediately realized that the drug dasatinib, which targets this pathway, would be a logical choice to use against these cancers," Cheresh said.

Experimenting on a pre-clinical model of pancreatic cancer, the researchers have confirmed that tumour cells with the receptor responded to the drug, while those not expressing receptors did not.

Cheresh pointed to pancreatic cancer tumours, approximately 60 percent of which carry the marker on the tumour cell surface.

"We would argue that pancreatic cancer patients with alpha-v beta-3 would respond to dasatinib," he said.

According to him, tumours that lack the marker appear to be resistant to the drug.

"We discovered an unexpected pathway that accounts for increased malignancy in a population of some of the most dangerous cancers," he said, noting that the marker could be identified by a biopsy.

"There are features of the findings that allow us to implicate dasatinib not just for a single tumour type, but for all tumours with the malignant signature," he added.

Dr. Barbara Parker, medical director of oncology services at the Moores UCSD Cancer Center, said: "These observations suggest a strategy for testing the effectiveness of dasatinib in breast cancer patients who are positive for the alpha-v beta-3 receptor."

A research article on the study has been published in the online edition of the journal Nature Medicine.

Source: ANI

News A-Z
News Category
What's New on Medindia
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
How to Battle Boredom during COVID
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Reiki and Pranic Healing Cancer Facts Cancer Tattoos A Body Art Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Recommended Reading
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of ....
Common Lifestyle Habits that Cause Diseases
Cigarette smoking, unhealthy diets, overuse of alcohol, and physical inactivity are some of the most...
Health Benefits of Dandelion Plant
What is dandelion? Dandelion greens are nutrition powerhouses with a wide range of health benefits. ...
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...
Non-Communicable Diseases
Non-Communicable Diseases (NCDs) are a group of chronic non-infectious diseases which include Cardio...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use